3Gover AU. Impact of the antibiotic dosage schedule on efficacy in experiment softt tissue infection[J]. Scan J Infect Dis,1990,74. (suppl):147.
4James JK, Palmer SM, Levin DP, et al. Comparison if convientional dosing verse continuous-infusion vaneomycin therapy for patients with suspected or documented gram-positive infections [ J]. Antimicobial Agents Chemother,1996,40 : 696.
5Tumidge JD, Gudmundsson S, Vogelman B, et al. The postantibiotic effect of antifungal agents against common pathogenic yeasts[J]. Journal of Antimicobial Chemother, 1994,34 : 83.
6Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/phamacodynamic(PK/PD) modeling[J], Int J Clinical Phamaco Therapeutics. 1997,35(10):401.
7Vogelrnan B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model[J]. J Infect Dis, 1988,158:831-847.
8Craig WA. Antimicrobial resistance issues of the future[J]. Diagn Microbiol Infect Dis, 1996,25:213-217.
9Tomqvist IO, Holm SE, Cars O. Phamacodynamic effects of Stabinhibitory antibiotic concentrations[J]. Scand J Infent Dis, 1991(Supple),74:94-101.
10Zhao XL, Drlica K. Restricting the selection of antibiotic resistant mutants: a general strategy derived from fluoroquinolone studies [ J ]. Clin Infect Dis,2001,33(supple) : 147-156.
